Measuring real-time influences of mental and tangible resources on men's TB treatment lapses and adherence behaviors

Ended Project Grant Awarded Last action

Award ID
R21AI163977
Recipient
Awarding agency
Obligated
$790,791

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date
Originally
Funding
  • $618,711.62 Federal
  • $172,079.00 Non-federal
Place of performance
South Africa

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
In 2018, approximately 10 million people developed TB disease globally, of which men aged =15 years accounted for over 50% of the cases. South african national TB prevalence studies have reported that men had a higher burden of TB, a lower case detection and larger reporting gaps compared to women. An analysis of south africa's TB care cascade revealed that only 53% of TB patients completed treatment. Most strikingly, TB in south africa is responsible for a large proportion of the difference in life expectancy between men and women. For south africa to contribute to the end TB strategy target of halving TB incidence by 2025, IT is imperative to implement effective interventions to support engagement and retention in TB care, especially among men. This study will develop a method to gather factors and resources influencing TB treatment in real-time, by integrating modified ecological momentary assessments (MEMA) with medication event-monitoring system (MEMS) and assessing its feasibility. This study will be conducted over two aims. In aim 1, we will integrate EMA and MEMS and then determine functionality and usability. This aim will be conducted over two phases. In phase 1, the research study team will integrate the wisepill technology (MEMS) with redcap and conduct a functionality simulation with study staff. In phase 2, a usability assessment of the MEMA-MEMS platform will be conducted with 20 participants, 10 men and 10 women. This phase will involve a think-aloud method and 30-day test using the MEMA-MEMS platform with a study mobile phone. Findings will inform the final MEMA-MEMS platform for aim 2. In aim 2, we will conduct an observational cohort study with 60 participants (30 men and 30 women) initiating TB treatment. All participants will be trained on how to use the MEMA-MEMS platform and provided a study mobile phone. Every 28 days, they will return to the clinic study site to refill their wisepill with medication. During the study, each participant will receive random and event memas based on their dosing behaviors. Participants will be interviewed at enrollment, during continuation and post-continuation stages of treatment, to assess feasibility, acceptability, willingness and safety using interviews and surveys. We will also collect preliminary data to understand psychosocial and contextual factors influential in TB treatment across the continuum, results will be used to inform subsequent study design. The results of this study will inform a larger R01 observational study that will determine what resources are needed at particular times during treatment to support adherence, and determine what resources are generalizable to all and distinctive for men such that an intervention may be developed and tested to support their adherence and TB treatment outcomes.

Transactions

Action Federal Non-federal Date
Amendment -$12 $0
Amendment $137,283 $0
Amendment $137,283 $0
Amendment $172,079 $0
Original award $172,079 $172,079

Quick answers

Who received award R21AI163977?

R21AI163977 was awarded to Desmond Tutu Health Foundation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 5, 2021.

How much is award R21AI163977 worth?

$790,791 has been obligated on R21AI163977: $618,712 in federal funding and $172,079 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login